Forbion Capital Partners

company

About

Forbion Capital Partners is a private equity and venture capital firm for making investments in buyouts.

  • 11 - 50

Details

Industries
Biotechnology,Health Care,Venture Capital
Founded date
Jan 1, 2006
Number Of Employee
11 - 50
Operating Status
Active
Investor Type
Venture Capital

Forbion Capital Partners is a Netherlands-based venture capital firm focused on investing in life sciences companies in drug development as well as MedTech companies addressing high medical needs. Forbion's investment team of nine investment professionals has built an impressive performance track record since the late nineties with successful investments in Rhein Biotech, Crucell, Neutec, Glycart, Borean, Impella, Alantos, Acorda, Fovea and PanGenetics. Current assets under management exceed €400m ($500m), split between three active funds. Finally, Forbion co-manages BioGeneration Ventures, an early stage fund focused on academic spin-outs and seed investments in the Netherlands.

Investments

Number of Investments
Number of Lead Investments
11
1
Forbion Capital Partners has made 11 investments. Their most recent investment was on Nov 22, 2022, when CatalYm raised €50M.
Date Company Name
Round Money Raised Industry Lead Investor
Nov 22, 2022 CatalYm
Series C €50M Biotechnology
Series B $53M Biopharma Yes
Nov 19, 2020 CatalYm
Series B €50M Biotechnology
Sep 8, 2017 Replimune Group
Series B $55M Biotechnology
Aug 5, 2016 CatalYm
Seed Biotechnology